S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
LifeStance Health Group, Inc. (NASDAQ:LFST) announced the resignation of William Miller from its board of directors and all related committees, effective immediately as of Tuesday. The company stated that Miller’s resignation did not result from any disagreement with the company.
Following Miller’s departure, the board appointed Sarah Personette as a director on Wednesday. According to the company’s statement, Personette received an initial award of 74,766 restricted stock units under LifeStance Health Group’s 2021 Equity Incentive Plan. The restricted stock units will vest according to a time-and performance-based agreement, contingent on Personette’s continued service on the board.
The information is based on a press release statement included in a recent SEC filing. With the stock trading at $5.55, analysts maintain a bullish outlook with price targets ranging from $6.50 to $10.00. Discover more insights and 7 additional key ProTips about LifeStance Health Group in the comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, LifeStance Health reported its earnings for the second quarter of 2025, showcasing a financial performance that exceeded revenue expectations. The company achieved an earnings per share of -$0.01, which was better than the anticipated -$0.03. Revenue for the quarter reached $345 million, slightly surpassing the forecasted $345.05 million and reflecting an 11% year-over-year increase. In addition to its financial results, LifeStance Health announced a change in its board of directors. Sarah Personette has been appointed to the board, effective immediately, as William Miller steps down after five years of service. These developments highlight ongoing changes within the company as it navigates its financial and governance landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.